(Reuters) - Drug development and approval in the world's second largest pharmaceutical market is notoriously slow, with drugs coming to market on average four years after they have first been sold overseas, hampered by the high development costs and a lack of volunteers for clinical trials.
Out of 150 new products launched in the world between 2002 and 2006, only 32 or 22 percent have been launched in Japan, according to pharmaceutical industry research firm IMS.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment